The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients
Open accessAbstract
AIMS: Renin-angiotensin-aldosterone system (RAAS) inhibitors are well established for the reduction in cardiovascular morbidity, but their impact on all-cause mortality in hypertensive patients is uncertain. Our objective was to analyse the effects of RAAS inhibitors as a class of drugs, as well as of angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor blockers (ARBs) separately, on all-cause mortality. METHODS AND RESULTS: We performed a pooled analysis of 20 cardiovascular morbidity-mortality trials. In each trial at least two-thirds of the patients had to be diagnosed with hypertension, according to the trial-specific definition, and randomized to treatment with an RAAS inhibitor or control treatment. The cohort included 158 998 patients (71 401 RAAS inhibitor; 87 597 control). The incidence of all-cause death was 20.9 and 23.3 per 1000 patient-years in patients randomized to RAAS inhibition and controls, respectively. Overall, RAAS inhibition was associated with a 5% reduction in all-cause mortality (HR: 0.95, 95% CI: 0.91-1.00, P= 0.032), and a 7% reduction in cardiovascular mortality (HR: 0.93, 95% CI: 0.88-0.99, P= 0.018). The observed treatment effect resulted entirely from the class of ACE inhibitors, which were associated with a significant 10% reduction in all-cause mortality (HR: 0.90, 95% CI: 0.84-0.97, P= 0.004), whereas no mortality reduction could be demonstrated with ARB treatment (HR: 0.99, 95% CI: 0.94-1.04, P= 0.683). This difference in treatment effect between ACE inhibitors and ARBs on all-cause mortality was statistically significant (P-value for heterogeneity 0.036). CONCLUSION: In patients with hypertension, treatment with an ACE inhibitor results in a significant further reduction in all-cause mortality. Because of the high prevalence of hypertension, the widespread use of ACE inhibitors may result in an important gain in lives saved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Mochizuki, S., Dahlöf, B., Shimizu, M., Ikewaki, K., Yoshikawa, M., Taniguchi, I., Ohta, M., Yamada, T., Ogawa, K., Kanae, K., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60669-2 · Cited by 347
RetractedSawada, T., Yamada, H., Dahlof, B., Matsubara, H., & for the KYOTO HEART Study Group (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp363 · Cited by 167
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142
Self-citationBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,889
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00011 · Cited by 1,409
Pepine, C. J., Handberg, E. M., Cooper-DeHoff, R. M., Marks, R. G., Kowey, P., Messerli, F. H., Mancia, G., Cangiano, J. L., Garcia-Barreto, D., Keltai, M., et al. (2003) · JAMA · doi:10.1001/jama.290.21.2805 · Cited by 1,286
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Messerli, F. H., Mancia, G., Conti, C. R., Hewkin, A. C., Kupfer, S., Champion, A., Kolloch, R., Benetos, A., & Pepine, C. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00005 · Cited by 779
Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Plate, K., Berger, J., Zidek, W., Dominiak, P., Diener, H. C., & the MOSES Study Group (2005) · Stroke · doi:10.1161/01.str.0000166048.35740.a9 · Cited by 766
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660
Dagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69201-5 · Cited by 514
Self-citationBlood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
(2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280bad9b4 · Cited by 414
Results of the pilot study for the Hypertension in the Very Elderly Trial
Bulpitt, C. J., Beckett, N. S., Cooke, J., Dumitrascu, D. L., Gil-Extremera, B., Nachev, C., Nunes, M., Peters, R., Staessen, J. A., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200312000-00030 · Cited by 296
Strauss, M. H., & Hall, A. S. (2006) · Circulation · doi:10.1161/circulationaha.105.594986 · Cited by 249
Thompson, A. M. (2011) · JAMA · doi:10.1001/jama.2011.250 · Cited by 215
Bangalore, S., Kumar, S., Wetterslev, J., & Messerli, F. H. (2011) · BMJ · doi:10.1136/bmj.d2234 · Cited by 147
Yui, Y., Sumiyoshi, T., Kodama, K., Hirayama, A., Nonogi, H., Kanmatsuse, K., Origasa, H., Iimura, O., Ishii, M., Saruta, T., et al. (2004) · Hypertension Research · doi:10.1291/hypres.27.181 · Cited by 145
The biochemistry of the renin-angiotensin system and its role in hypertension
Skeggs, L. T., Dorer, F. E., Kahn, J. R., Lentz, K. E., & Levine, M. (1976) · The American Journal of Medicine · doi:10.1016/0002-9343(76)90888-3 · Cited by 139
Kasanuki, H., Hagiwara, N., Hosoda, S., Sumiyoshi, T., Honda, T., Haze, K., Nagashima, M., Yamaguchi, J.-I., Origasa, H., Urashima, M., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp101 · Cited by 111
Tocci, G., Paneni, F., Palano, F., Sciarretta, S., Ferrucci, A., Kurtz, T. W., Mancia, G., & Volpe, M. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.8 · Cited by 88
Proteinuria and Risk for Stroke and Coronary Heart Disease During 27 Years of Follow-up
Madison, J. R., Spies, C., Schatz, I. J., Masaki, K., Chen, R., Yano, K., & Curb, J. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.884 · Cited by 61
Huang, G., Xu, J., Liu, J., He, Y., Nie, X.-L., Li, Q., Hu, Y., Zhao, S.-Q., Wang, M., Zhang, W., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02460.x · Cited by 52
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial
Ogihara, T., Fujimoto, A., Nakao, K., & Saruta, T. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.9.1195 · Cited by 46
Marketou, M. E., Kintsurashvili, E., Papanicolaou, K. N., Lucero, H. A., Gavras, I., & Gavras, H. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.20 · Cited by 46
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
Hypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Metadata
- Authors
- van Vark, L. C., Bertrand, M., Akkerhuis, K. M., Brugts, J. J., Fox, K., Mourad, J.-J., & Boersma, E.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-17
- Volume
- 33
- Issue
- 16
- Pages
- 2088-2097
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2119577709
- Cited by
- 460
- References
- 50
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.